Determination of Prevalence and Features of HRRm mCRPC (ADAM) (ADAM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04712890 |
Recruitment Status :
Recruiting
First Posted : January 15, 2021
Last Update Posted : February 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Study design:
This study is local, multi-center, prospective, cohort study to collect real world data related mCRPC patients, prevalence of HRRm and to assess possible influence of HRRm on treatment outcomes. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Treatment assignment will be done according to the current practice.
Data Source(s):
For testing archival samples (formalin fixed and paraffin embedded [FFPE]) from primary tumor will be used . 15 HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D and RAD54L) will be analyzed using NGS in dedicated central laboratory facilities. Choice of laboratory for each center will be made based on logistical proximity. Each NGS laboratory will have to determine and report clinical significance of alterations found using database search or other predictors to classify variants as deleterious or suspected deleterious. VUS have to be reported separately. Benign variants will be not reported in this study.
All clinical and demographic data for patients with finished therapy will be collected in prospective or retrospective (where applicable) manner during the study visits. The second visit will take place when the disease progression or death is occurs or in a year after the first visit whichever happens first. Data will be entered in the eCRF. The site investigator will be responsible for ensuring that all required data is collected and entered into the eCRF with the involvement of clinical research organization.
It is estimated that approximately 300 patients will be enrolled in the first stage. After interim analysis total number of the patients can be increased, depending on the number of NGS failures. It is estimated that approximately 30 sites in total will be participating in the study.
Condition or disease |
---|
HRRm mCRPC |
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Multi-center, Non-interventional, Prospective Cohort Study for Determination of Prevalence and Features of HRRm mCRPC (ADAM) |
Actual Study Start Date : | October 23, 2020 |
Estimated Primary Completion Date : | October 31, 2022 |
Estimated Study Completion Date : | October 31, 2022 |
- Differences in demographics between patients with HRRm and HRRwt mCRPC [ Time Frame: Up to 1 year ]
- Differences in treatment patterns between patients with HRRm and HRRwt mCRPC [ Time Frame: Up to 1 year ]
- Differences in clinical characteristics between patients with HRRm and HRRwt mCRPC [ Time Frame: Up to 1 year ]
- Progression-free survival (PFS) rate (time to documentation of objective tumor progression/relapse) stratified by tissue HRR-related gene mutation status and by treatment pattern [ Time Frame: Up to 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Male 18 years age or older
- Provision of written informed consent
- Histologically confirmed diagnosis of prostate cancer
- Documented evidence of metastatic castration resistant prostate cancer (mCRPC)
- Patients who are on the first line therapy or already received one line of therapy due to mCRPC previously
- Availability of archival FFPE tissue from primary prostate tumor
- Availability of medical history (e.g. out-patient medical records or disease histories for hospitalized patients)
Exclusion Criteria:
• Patients participating in clinical studies

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04712890
Russian Federation | |
Altay regional oncological hospital | Not yet recruiting |
Barnaul, Russian Federation | |
Contact: Sergey Varlamov 7-3812-258217 akod@akod22.ru | |
Chelyabinsk oncology center | Recruiting |
Chelyabinsk, Russian Federation | |
Contact: Galina Gopp 8 (351) 214-88-88 onco74@chelonco.ru | |
Sverdlovsk regional oncological hospital | Recruiting |
Ekaterinburg, Russian Federation | |
Contact: Aleksandr Orlov +7 (343) 356-17-31 cood@uralonco.ru | |
Moscow city oncological hospital N 2 | Recruiting |
Moscow, Russian Federation | |
Contact: Aleksandr Bystrov 7 495 536 01 00 gob62@zdrav.mos.ru | |
Privolzhsky regional medical center | Recruiting |
Nizhniy Novgorod, Russian Federation | |
Contact: Vagif Adtuev +7 (831) 428 81 88 pomc@bk.ru | |
Clinical oncology hospital of Omsk | Recruiting |
Omsk, Russian Federation | |
Contact: Evgeny Kopyltsov 7-3812-258217 minzdrav@minzdrav.omskportal.ru |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT04712890 |
Other Study ID Numbers: |
D133HR00008 |
First Posted: | January 15, 2021 Key Record Dates |
Last Update Posted: | February 25, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared. |
Time Frame: | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
Access Criteria: | When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
URL: | https://astrazenecagroup-dt.pharmacm.com/DT/Home |
HRRm mCRPC |